Insider Selling: Natera (NASDAQ:NTRA) Director Sells 48,419 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Herm Rosenman sold 48,419 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $227.42, for a total transaction of $11,011,448.98. Following the completion of the sale, the director owned 20,342 shares in the company, valued at approximately $4,626,177.64. This trade represents a 70.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Natera Price Performance

Shares of NTRA stock traded down $1.00 on Tuesday, hitting $227.40. The stock had a trading volume of 874,175 shares, compared to its average volume of 1,509,833. The company’s 50 day moving average price is $209.04 and its 200-day moving average price is $177.74. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $246.90. The firm has a market capitalization of $31.45 billion, a P/E ratio of -99.30 and a beta of 1.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.26) earnings per share. On average, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Wells Fargo & Company boosted their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Fifteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and an average target price of $229.12.

Institutional Trading of Natera

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Natera by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after buying an additional 282,826 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. State Street Corp increased its position in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.